Campath®
Learn More About Cancer Treatment Centers Of America: Chat with Us | Email Us
Belonging to a group of artificially produced pure antibodies (also known as monoclonal antibodies), Campath® is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL), whose disease has progressed despite treatment with alkylating agents and fludarabine therapy.
For patients with this distinct form of leukemia, Campath® has been shown to target CD52, a distinct and harmful protein, by triggering the body's own immune system in order to target and destroy cancer cells. Campath® is the first monoclonal antibody approved by the U.S. FDA for the treatment of patients with B-CLL.
At Cancer Treatment Centers of America (CTCA), your team of cancer specialists will work together to determine if Campath® is the right treatment option for you. Our unique, individualized approach to cancer treatment ensures that you remain well informed regarding the expectations associated with Campath®, as well as all other treatment options.
Utilizing a powerful combination of traditional, new and complementary therapies, CTCA works to treat your cancer on all fronts by treating all of you, not just your cancer. Learn more about our unique approach to cancer treatment. Chat now with an Oncology Information Specialist to discover if CTCA is the right cancer treatment facility for you.
Campath® is an antibody which attacks cancerous cells. Campath® also may affect noncancerous cells, and as such, your immune system may be weakened, increasing the likelihood of infection. At Cancer Treatment Centers of America (CTCA), your cancer doctors will provide medication to help mitigate the chance of infection should Campath® be selected as part of your individualized plan of treatment.
Common side effects associated with Campath® treatment include:
- Fatigue
- Fever
- Shaking
- Nausea
- Itching
- Vomiting
- Rash
- Low blood pressure
- Reduced blood cell counts
It is important to note that these are not all of the side effects associated with Campath® treatment.
As part of our personalized approach to cancer treatment, your team of cancer experts will ensure that you are well informed regarding the side effects and expectations of Campath®, as well as all other medications used during your care. Throughout each phase of your treatment, you will be closely monitored by your team of specialists. You will also be involved all decisions made.
Campath® is indicated for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL), whose diseased has progressed following treatment with other chemotherapeutic agents. Campath® is a monoclonal antibody which works by attaching itself to the antigen known as CD52, and destroying it with help from the immune system.
At Cancer Treatment Centers of America (CTCA), your doctors will determine if Campath® is the right treatment option for you. Campath® is not right for all B-CLL patients, including those with deficiencies of the immune system. Your unique needs will be assessed at our cancer facility, and a unique combination of therapies will be developed which is right for you.
Contact an Oncology Information Specialist today at 800-615-3055 to learn more about our whole-patient approach to cancer treatment.
CTCA treats many types of cancer. If you would like more information on treatment options available at our cancer hospitals, please contact one of our cancer information specialists at 1-800-615-3055 or click here to chat.